AdAI, a new AI advertising platform incubated by Revolution Venture Studios, launched on September 11, 2026. Its pitch: AI agents that remake a company's existing ads in seconds, working from that company's own brand assets and guidelines, informed by real performance data pulled from Meta and Google. Co-founder and CEO Kevin Bartley framed the problem it solves plainly: "Quality has never been so critical, and yet in such short supply." Co-founder Kyle Robertson, also a Managing Partner at Revolution Venture Studios, called the launch "the moment for change, and for a new kind of adtech company."
The sentence worth reading twice is how the platform describes its own output. The company says the result is a finished ad "that can be used without the rounds of editing and review typically required with AI-generated creative." Not faster editing. No editing. AdAI is already running this in production for what it describes as a six-figure telehealth account, in an industry where a misworded claim turns into a compliance problem fast.
What's actually being automated here, and what isn't
There's a real, defensible idea inside this launch. Generating ad variants from a brand's own already-approved assets and its own rules, informed by real performance data instead of a guess, is exactly the kind of repetitive production work a system should absorb, not a person's afternoon. Bartley's other line, that the platform is "designing constraints" rather than chasing "extravagance," is the right instinct. A tool that has to stay inside a brand's own guidelines is a very different thing from a tool that invents a brand from nothing.
What doesn't hold up is calling the removal of review a quality feature. Review is where quality actually gets caught, or missed: the claim that oversells, the line that's technically on-brand and still a bad idea, the detail that reads wrong in a market the brief never anticipated. Skipping that step for a telehealth advertiser moves the moment someone would have caught a problem from before an ad goes out, to after, when a regulator or a customer catches it instead.
Where we draw the line
This is the maximiser-versus-replacer split again, except this time the founders are using maximiser language to sell a replacer product, and that gap is worth naming plainly. Bartley says quality is scarce and then ships a platform whose actual selling point is removing the step that produces quality. Robertson calls it "the moment for change," but the change on offer concentrates judgment inside the platform and strips it out of the team that used to hold it. That's the direction that turns a tool into something closer to a landlord: you don't own the review process anymore, you rent an outcome from a system that decided review wasn't worth keeping.
A telehealth account is already running ads with no human check between the system's output and the public. Here's what we'd build instead: automate the repetitive part, the variant generation, the data pull, the formatting, and leave the part that actually protects a brand, a regulator, and a patient in a person's hands. That's the version still worth trusting in two years, when the first bad AdAI-produced ad becomes its own news story.
This is the same standard behind every system Shery builds through Aparato. See what that actually looks like →